Private Equity
3 min read · 09 November 2017
2 min read · 08 November 2017
San Francisco-based Oyster Point Pharmaceuticals Inc., a developer of treatments for dry eye and other diseases of the ocular surface, has closed $22 million in Series A financing. New Enterprise Associates and Versant Ventures led the round.
1 min read · 08 November 2017
Plymouth, Minnesota-based Silk Technologies Ltd, a biotech company that uses silk protein to develop drugs that treat eye disease, has raised an undisclosed amount of Series A funding. The investor was Skyview Ventures.
1 min read · 08 November 2017
Fortuna Fix, a Canadian regenerative medicine company, has raised $25 million in Series B financing. The investors included Amgen Ventures.
1 min read · 08 November 2017
South San Francisco, California-based Tricida, Inc, a developer of oral drug therapies, has raised $57.5 million in Series D financing. The investors were Wellington Management Company LLP, Venrock Healthcare Capital Partners, Cormorant Asset Management, OrbiMed, Longitude Capital, Sibling Capital Ventures, Limulus Venture Partners and Vivo Capital.
1 min read · 08 November 2017
1 min read · 08 November 2017
2 min read · 07 November 2017
Venture capital firm EnerTech Capital has formed a strategic partnership with ENMAX Corp focused on emerging technologies in the utility industry. EnerTech and ENMAX, a Calgary provider of electricity to residential and commercial customers, will together explore commercialization strategies within ENMAX and opportunities available through the investor's global network. EnerTech, which has offices in Calgary, Montréal, Toronto and the United States, has invested in 63 energy and power companies since 1996. It is currently investing from its fourth fund, which raised $120 million in 2013.
3 min read · 07 November 2017
Houston-based private equity firm Genesis Park has raised over $148.5 million for its second fund, according to an SEC filing. The target is $250 million.
1 min read · 07 November 2017
